Clomipramine (Anafranil) in depressive patients with obsessive neurosis.
The authors express the view that, clinically, clomipramine (Anafranil, Geigy Pharmaceuticals) seems to be the treatment of choice for obsessive-compulsive illness. Clomipramine possesses a specific anti-obsessional property which is distinct from its antidepressant property. The optimal therapeutic dose from this study appears to be in the range of 175 mg to 225 mg a day. Minor reversible adverse reaction gradually decreases with the increase of duration of treatment.